April 07, 2023
33 min listen
Save
EyePoint Pharmaceuticals’ EYP-1901: Promising Novel Drug Delivery System
In this episode, I chat with Nancy Lurker, CEO and board director, about EyePoint Pharmaceuticals and their latest treatments and trials.
Brought to you by Alcon
- Welcome to another exciting episode of Eye Care insider :13
- Intro Nancy Lurker :22
- Lurker’s background :58
- EyePoint Pharmaceuticals: the origin and transition 2:29
- Yutiq and long-acting drug delivery systems 6:07
- Additional indications for Yutiq 8:30
- What is the key factor in delivering this longer durability? 16:13
- Any consideration of looking at superiority of visual acuity and anatomical OCT gains? 21:47
- Is the primary focus wet AMD? Or are you also looking at NPDR and DME as potential indications? 24:19
- Investor information and neural protection data 29:01
- What is the most important issue that the field of ophthalmology is currently facing? 30:38
- Thanks for listening 32:37
We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. You can find Nancy Lurker at @EyePointCEO and @EyePointPharma.
Nancy Lurker is the board director and CEO of EyePoint Pharmaceuticals.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Lurker is the board director and CEO of EyePoint Pharmaceuticals. Mali reports he is founder and CEO of Mali Enterprises; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI.
